Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight The MAReport: read the Summer/Fall 2018 issue of the MAReport newsletter! This quarter, Health Professions Coordinator Erin Seger wrote about her experiences at the 17th annual Philadelphia Trans Wellness Conference, and LGBT health information needs in her article, “LGBT Health Information Resources.” Member Highlights: Stony Brook University, Southampton, NY – learn about how the Applied Health Informatics Program at Stony Brook used NNLM MAR funding to conduct a Wellness Fair for seniors, and later...
Source: NN/LM Middle Atlantic Region Blog - October 19, 2018 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

Intuitive Surgical jumps on Q3 beats, increased procedures outlook
Shares of Intuitive Surgical (NSDQ:ISRG) got a pre-market bump today after the robot-assisted surgery pioneer posted third-quarter results that beat the consensus forecast, despite lower profits, and upped its outlook on procedure growth for the year. Sunnyvale, Calif.-based Intuitive posted profits of $292.5 million, or $2.45 per share, on sales of $920.9 million for the three months ended Sept. 30. That amounts to a -2.0% profit decline on top-line growth of 14.0% compared with Q3 2017. Adjusted to exclude one-time items, earnings per share were $2.83, 17¢ ahead of the consensus on Wall Street, where analysts w...
Source: Mass Device - October 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured MassDevice Earnings Roundup Robotics Wall Street Beat Intuitive Surgical Source Type: news

Fresenius plunges on missed prelims, guidance cut
Fresenius (NYSE:FMS) shares closed down some $17% yesterday after it cut its outlook for the rest of the year on lower-than-expected third-quarter results. The German dialysis giant released preliminary figures for the three months ended Sept. 30, saying it expects to report profits of €285 million on sales of €4.06 billion. Analysts were looking for sales of €4.12 billion. Fresenius cut its forecast for 2018, saying it now expects to log adjusted net income growth of 2% to 3%, down from 7% to 9% previously. Sales growth is now pegged at 2% to 3%, compared with 5% to 7% previously, &ldquo...
Source: Mass Device - October 18, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Dialysis Featured Mergers & Acquisitions Wall Street Beat Fresenius Source Type: news

Abbott slips on narrowed earnings guidance
Abbott shares slipped in pre-market trading today after the company narrowed its earnings outlook for the rest of the year, after just meeting both its own forecast and the consensus Wall Street outlook. The Chicago-area healthcare giant’s profits for the three months ended Sept. 30 were off -6.6% at $563 million, or 32¢ per share, despite sales growth of 12.1% to $7.66 billion compared with Q3 2017. Adjusted to exclude one-time items, earnings per share were 75¢, dead even with the top end of Abbott’s guidance and the average on The Street, where analysts were looking for sales of $7.65 billion. &ldq...
Source: Mass Device - October 17, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured MassDevice Earnings Roundup Wall Street Beat Abbott Source Type: news

J & J beats profit estimates, lifts outlook on pharma unit strength
Johnson& Johnson reported slightly better-than-expected third quarter profit and raised its full-year forecast on Tuesday as increased demand for cancer drugs and immune disorder treatments powered strong results for its pharmaceutical unit. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

UnitedHealth, Optum Remain On A Roll As Medicare Advantage Takes Off
UnitedHealth Group's third quarter profits jumped 28% on growth of health insurance and Optum health services businesses. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 16, 2018 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Tags: NYSE:UNH NYSE:CVS NYSE:HUM NYSE:AET NYSE:CI Source Type: news

Johnson & Johnson edges past profit estimates, lifts outlook
Johnson& Johnson reported slightly better-than-expected quarterly profit on Tuesday and pushed its full-year forecast higher, as demand for its cancer drugs Zytiga and Imbruvica helped offset falling sales of arthritis treatment Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson profit beats, lifts forecast on cancer drug demand
Johnson& Johnson on Tuesday reported quarterly profit above estimates and raised its full-year forecast, as demand for its cancer drugs Zytiga and Imbruvica helped offset decline in sales of blockbuster drug, Remicade. (Source: Reuters: Health)
Source: Reuters: Health - October 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Johnson & Johnson ’ s Q3 numbers top estimates
Third-quarter sales and earnings for Johnson & Johnson (NYSE:JNJ) topped the consensus forecast, prompting the healthcare giant to raise its outlook for the rest of the year. New Brunswick, N.J.-based J&J posted profits of $3.93 billion, or $1.44 per share, on sales of $20.35 billion for the three months ended Sept. 30, for a bottom-line gain of 4.5% on sales growth of 3.6% compared with Q3 2017. Adjusted to exclude one-time items, earnings per share were $2.05, 2¢ ahead of Wall Street, where analysts expected sales of $20.05 billion. “We are pleased with our strong third-quarter performance, which refle...
Source: Mass Device - October 16, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured MassDevice Earnings Roundup Wall Street Beat johnsonandjohnson Source Type: news

ConvaTec CEO Departs Suddenly as Company Slashes Profit Forecast
ConvaTec shares plunged 33.10% ($74.20) Monday after the company slashed its revenue guidance and announced the departure of CEO Paul Moraviec. The advanced wound care company said Moraviec informed the board that he "wishes to retire." He stepped down as CEO and ceased to be a company director immediately, ConvaTec noted. Rick Anderson, a non-executive director, will step in as the interim CEO and will be based at the company's headquarters in Reading, United Kingdom. “We have made significant progress during my time as chief executive officer and I am confident that ConvaTec now has the strong...
Source: MDDI - October 16, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight The MAReport: read the Summer/Fall 2018 issue of the MAReport newsletter! This quarter, All of Us Community Engagement Coordinator Veronica Leigh Milliner talks about opportunities to incorporate genetics into health programming in her article, “Your Family, Your History, Your Health: Genetics Resources.” New Funding Opportunity: NNLM MAR is pleased to announce the availability of funding through NLM’s partnership with the NIH All of Us Research Program. We are now accepting applications for...
Source: NN/LM Middle Atlantic Region Blog - October 12, 2018 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

Citigroup profit beats on higher bond trading, lower costs
Citigroup Inc reported a better-than-expected quarterly profit on Friday, helped by lower expenses, higher bond trading revenue and strength in its consumer banking business in Mexico. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

JPMorgan's consumer banking strength offsets bond trading weakness
JPMorgan Chase& Co reported a better-than-expected quarterly profit on Friday as gains from higher interest rates and growth in loans helped the bank offset weakness in bond trading revenue. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Citigroup profit beats on higher bond trading, LatAm growth
Citigroup Inc reported a better-than-expected quarterly profit on Friday, helped by higher bond trading revenue and strength in its consumer banking business in Mexico. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight The MAReport: the Summer/Fall 2018 issue of the MAReport newsletter is now available! This quarter, Executive Director Kate Flewelling wrote about how the National Library of Medicine and National Network of Libraries of Medicine are responding to the opioid crisis, including details on a new class that will be offered for the first time on November 28. National Network of Libraries of Medicine News Funding Applications Due: NNLM MAR has funding available for two grants of $19,000. Libraries, community-based organizations, ...
Source: NN/LM Middle Atlantic Region Blog - October 5, 2018 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

AtriCure posts Street-topping Q3 prelims
AtriCure (NSDQ:ATRC) late yesterday released preliminary earnings for the third quarter that beat consensus on Wall Street. The Mason, Ohio-based company said it expects to post sales of $49.9 million, which reflects growth of approximately 18.5% over its third quarter from the previous fiscal year. US-based revenue is expected to be $39.8 million, while international sales are expected to be $10.2 million, the company said. Atricure said it expects to post losses of between $6 and $7.5 million for the quarter. The preliminary sales expectations are just ahead of the $46.8 million consensus on Wall Street. “Our ...
Source: Mass Device - October 4, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat AtriCure Inc. Source Type: news

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight September is National Preparedness Month. Disasters Happen. Prepare Now. Learn How. This week: Save for an Emergency. The MAReport: the Summer/Fall 2018 issue of the MAReport newsletter is now available! This quarter, Education & Healthy Literacy Coordinator Michelle Burda is challenging YOU to raise health literacy awareness in your library, organization or community! Check out her article on Health Literacy Month for tools and resources you can use to promote health literacy during the month of October, and all year l...
Source: NN/LM Middle Atlantic Region Blog - September 28, 2018 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

Hologic lowers Cyosure revenue outlook in response to FDA warning on ‘ vaginal rejuvenation ’ products
Hologic (NSDQ:HOLX) today lowered the revenue expectations for its Cynosure division by $15 million to take into effect lost and reduced sales associated with an FDA warning from last month which raised concerns about the validity and functionality of “vaginal rejuvenation” products and procedures. Last month the company said that Cynosure will suspend the marketing and distribution of its TempSure Vitalia handpieces and probes after the FDA released a warning about a lack of evidence to support certain “vaginal rejuvenation” products in July. The reduced revenue expectations are due ...
Source: Mass Device - September 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat Cynosure Inc. Hologic Source Type: news

Hologic lowers Cynosure revenue outlook in response to FDA warning on ‘ vaginal rejuvenation ’ products
Hologic (NSDQ:HOLX) today lowered the revenue expectations for its Cynosure division by $15 million to take into effect lost and reduced sales associated with an FDA warning from last month which raised concerns about the validity and functionality of “vaginal rejuvenation” products and procedures. Last month the company said that Cynosure will suspend the marketing and distribution of its TempSure Vitalia handpieces and probes after the FDA released a warning about a lack of evidence to support certain “vaginal rejuvenation” products in July. The reduced revenue expectations are due ...
Source: Mass Device - September 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat Cynosure Inc. Hologic Source Type: news

Avinger shareholders accept $5 million settlement
The plaintiffs in a class action suit against Avinger (NSDQ:AVGR) have approved the $5 million settlement that the company offered in March. Shareholders sued the company and several of its officers and directors claiming that they made false and misleading statements about Avinger’s original product, Pantheris, in its 2015 initial public offering. Avinger makes image-guided, catheter-based atherectomy systems for treatment of peripheral artery disease. The company has already paid its $1.75 million portion of the settlement. Avinger sold approximately 5 million shares to members of the public in its IPO at $13....
Source: Mass Device - September 13, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Cardiovascular Catheters Food & Drug Administration (FDA) Initial Public Offering (IPO) Legal News Avinger Source Type: news

Neovasc talks note holders into another year, announces 1-for-100 reverse stock split
Neovasc (NSDQ:NVCN) said today that holders of its senior secured convertible notes, originally due May 17, 2019, have agreed to extend the maturity of the notes from next year to May 17, 2020, and said yesterday it will initiate a reverse stock split as it looks to regain compliance with minimum bid price requirement of the Nasdaq stock market. The Vancouver-based company said it entered into a waiver agreement extending the date a year and permitting an increase for the company’s quarterly cash burn as defined in the notes. “We have negotiated with the debt note-holders and, though we have little to no l...
Source: Mass Device - September 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Wall Street Beat Neovasc Inc. Source Type: news

TransEnterix submits FDA clearance bid for Senhance ultrasonic instrumentation
TransEnterix (NYSE:TRXC) said today it filed an FDA 510(k) submission for its Senhance Ultrasonic instrument system, designed to operate with its Senhance robotic platform. The Research Triangle Park, N.C.-based company said that the approval would allow the system to utilize ultrasonic devices designed to deliver controlled energy to ligate and divide tissue and minimize thermal injury to the surrounding structures. “Advanced energy devices, such as the one now developed for Senhance, represent the most common tools that surgeons utilize when performing challenging tissue dissections. Adding such capability to ...
Source: Mass Device - September 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Robotics Surgical TransEnterix Source Type: news

These Mass. companies generated the most profits in Q2
U.S. companies — including many in the Bay State — rebounded from a lackluster showing in the first quarter of the year with a surge in profits that's expected to fuel even more economic growth in the months ahead. The Commerce Department reported last week that after-tax profits among U.S. companies jumped 1 6.1 percent on a year-over-year basis during the quarter that ended June 30, qualifying as the largest such increase since 2012. Some of the biggest gainers in Massachusetts hail from the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 3, 2018 Category: Pharmaceuticals Authors: Jeff Jeffrey Source Type: news

These Mass. companies generated the most profits in Q2
U.S. companies — including many in the Bay State — rebounded from a lackluster showing in the first quarter of the year with a surge in profits that's expected to fuel even more economic growth in the months ahead. The Commerce Department reported last week that after-tax profits among U.S. companies jumped 1 6.1 percent on a year-over-year basis during the quarter that ended June 30, qualifying as the largest such increase since 2012. Some of the biggest gainers in Massachusetts hail from the… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 3, 2018 Category: Biotechnology Authors: Jeff Jeffrey Source Type: news

Medtronic ’ s Q1 tops The Street
Medtronic (NYSE:MDT) today posted fiscal first-quarter results that topped the consensus forecast on Wall Street and raised its sales outlook for the rest of fiscal 2019. The world’s largest medical device business put up profits of $1.08 billion, or 79¢ per share, on sales of $7.38 billion for the three months ended July 27, for a bottom-line gain of 5.8% on flat sales compared with fiscal Q1 2018. Adjusted to exclude one-time items, earnings per share were $1.17, 6¢ ahead of the consensus on Wall Street, where analysts were looking for sales of $7.24 billion. “We are executing against our plan, grow...
Source: Mass Device - August 21, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Medtronic Source Type: news

Accuray shares rise on Street-topping Q4, FY2018 earnings
Shares in Accuray (NSDQ:ARAY) rose today after the medical device maker beat expectations on Wall Street with its fourth quarter and full fiscal year 2018 earnings. The Sunnyvale, Calif.-based company posted losses of $946,000 or 1¢ per share, on sales of $113.8 million for the three months ended June 30, seeing losses shrink 82% while sales grew 1.5% compared with the same period last year. Losses per share were just ahead of the 2¢ consensus on Wall Street. For the full year, Accuray posted losses of $23.9 million, or 28¢ per share, on sales of $404.9 million, seeing losses shrink 19.2% while sales gr...
Source: Mass Device - August 17, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Accuray Inc. Source Type: news

Second Sight inks $5m private placement deal
Second Sight Medical (NSDQ:EYES) said today it inked a $5 million private placement deal with funds slated to support continued development and testing of its implantable visual prosthetic technology. The Los Angeles-based company said it is selling approximately 3.2 million shares of common stock at $1.55 per share to entities owned by its board chair Gregg Williams, effective on August 14. Second Sight said it expects to net gross proceeds of approximately $5 million to help support a feasibility study of its Orion cortical visual prosthesis system, continued development of its Argus 2s next-gen devices and collecti...
Source: Mass Device - August 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Wall Street Beat Second Sight Source Type: news

ReShape Lifesciences shares plunge on Q2 release, withdrawn offering
Shares in ReShape Lifesciences (NSDQ:RSLS) have fell 30% today after the weight loss device maker posted second quarter earnings that missed expectations on Wall Street and announced it terminated plans for an upcoming offering. The San Clemente, Calif.-based company posted losses of $35.3 million, or $14.23 per share, on sales of $653,369 for the three months ended June 30, seeing losses grow 415.3% while sales grew 602.1% compared with the same period last year. Losses per share were significantly behind the $1.79 consensus on Wall Street. “We have made a lot of meaningful progress this quarter at ReShape, wit...
Source: Mass Device - August 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat reshapelifesciences Source Type: news

OrthoPediatrics expands Indiana-based headquarters
OrthoPediatrics said yesterday it is planning a $1 million expansion of its Warsaw, Ind.-based headquarters, looking to double its warehouse space and add administrative spaces. The expansion will include the addition of open-concept offices and dedicated training and education facilities, the company said. A ground-breaking on the expansion is being held on August 16. “Indiana is known as one of the leading hubs for orthopedics, and we are excited to see this trend not only continue but strengthen with the commitment of companies like OrthoPediatrics. Our industry leaders are innovating new products and develop...
Source: Mass Device - August 15, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News OrthoPediatrics Corp. Source Type: news

Mount Sinai boosts profits in Q2 as more patients visit
Mount Sinai Medical Center saw a sharp increase in profits during the second quarter as it treated more patients. The non-profit hospital in Miami Beach earned $16 million, up from earnings of $3.9 million in the same period a year ago, according to a report to its bondholders. In the recent quarter, it received a special payment of $10.3 million from the state’s Lower Income Pool, which compensates hospita ls that provide a lot of charity and Medicaid care. MSMC President and CEO Steven Sonenreich… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 15, 2018 Category: Pharmaceuticals Authors: Brian Bandell Source Type: news

Avinger posts loss on disappointing sales
Avinger (NSDQ:AVGR) today posted a second-quarter losses-per-share that missed an analyst’s expectation, sending its share price down on Wall Street despite nearly halving its losses. The Redwood City, Calif.-based medical device maker reported losses of -$6.6 million, or -98¢ per share, on sales of $2.1 million for the three months ended June 30, 2018. That compares with losses of -$12.8 million during Q2 2017 and amounts to a -14% top-line slide. An analyst on The Street was looking for losses per share of -0.48¢ on sales of $2.6 million. Positive news for the quarter included FDA clearance and ...
Source: Mass Device - August 14, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Business/Financial News Cardiovascular Catheters Avinger Source Type: news

Rancho Cordova's Cesca Therapeutics reports $27.2 million loss on impairment of assets
Cesca Therapeutics Inc., a Rancho Cordova-based cell therapy company, said it incurred $27.2 million in charges against earnings last quarter for impairment in the value of assets. The impairment charges include $12.7 million to goodwill and $14.5 million to intangible assets, Cesca (Nasdaq: KOOL) said Monday in a news release. The write-down in the value of assets led to a second-quarter loss of $27.2 million, compared to a loss of $1.15 million in the year-earlier quarter . Revenue declined 43… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 14, 2018 Category: Biotechnology Authors: Felicia Alvarez Source Type: news

Rancho Cordova's Cesca Therapeutics reports $27.2 million loss on impairment of assets
Cesca Therapeutics Inc., a Rancho Cordova-based cell therapy company, said it incurred $27.2 million in charges against earnings last quarter for impairment in the value of assets. The impairment charges include $12.7 million to goodwill and $14.5 million to intangible assets, Cesca (Nasdaq: KOOL) said Monday in a news release. The write-down in the value of assets led to a second-quarter loss of $27.2 million, compared to a loss of $1.15 million in the year-earlier quarter . Revenue declined 43… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 13, 2018 Category: Pharmaceuticals Authors: Felicia Alvarez Source Type: news

Declining Sales Prompts Endologix to Hit the Strategic Reset Button
John Onopchenko has had his work cut out for him since being promoted to CEO of Endologix in May. The company's revenue dropped 6.1% in the fiscal year 2017 compared to the fiscal year 2016 after a manufacturing glitch interrupted sales of its top-selling device for abdominal aortic aneurysms (AAA). This and other issues led CEO John McDermott to resign earlier this year. "The leadership team and I have been working hard on reestablishing Endologix's credibility and reputation with our physicians and customers and building a culture of accountability, with the ultimate goal of deliv...
Source: MDDI - August 13, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Endologix shares plunge on Q2 earnings miss
Shares in Endologix (NSDQ:ELGX) have lost nearly 40% after the company released second quarter earnings that missed loss per share expectations on Wall Street and lowered its guidance for the full year. The Irvine, Calif.-based company posted losses of $23.9 million, or 28¢ per share, on sales of $44.7 million for the three months ended June 30, seeing losses grow 46.6% while sales shrunk 7.9% compared with the same period last year. Adjusted to exclude one-time items, losses per share were 18¢, just behind the 15¢ consensus on Wall Street. “Our second quarter results were in line with our ex...
Source: Mass Device - August 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Endologix Source Type: news

Orthofix Q2 shows shrinking profits
Orthofix (NSDQ:OFIX) this week posted second quarter earnings that beat expectations on Wall Street but showed growing losses. The Lewisville, Texas-based company posted profits of $925,000, or 5¢ per share, on sales of $111.6 million for the three months ended June 30, seeing profits shrink 97.6% while sales grew 2.4% compared with the same period last year. Adjusted to exclude one-time items, earnings per share were 42¢, ahead of the 36¢ consensus on The Street. “During the second quarter, we made excellent progress on our operating and margin improvement goals despite the impact of unexpected c...
Source: Mass Device - August 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Orthofix Source Type: news

Shares in Neovasc fall as Q2 shows growing losses
Shares in Neovasc (NSDQ:NVCN) fell today after the medical device maker posted second quarter earnings that showed growing losses. The Vancouver-based company posted losses of $49.1 million, or 4¢ per share, on sales of $405,247 for the three months ended June 30, seeing losses increase a staggering 1032% while sales shrunk 68.9% compared with the same period during the previous year. “Over the last several months we have successfully executed on a number of our clinical and operational goals, as we work our way through what has been a challenging period for our shareholders. We remain confident in our...
Source: Mass Device - August 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Neovasc Inc. Source Type: news

Wright Medical shares rise on Q2 earnings Beat
Shares in Wright Medical (NSDQ:WMGI) rose today in pre-market trading after the medical device maker beat expectations on Wall Street with its second quarter results. The Amsterdam-based company posted losses of $67.7 million, or 64¢ per share, on sales of $205.4 million for the three months ended July 1, seeing losses grow 64.5% while sales grew 14.3% compared with the same period last year. Adjusted to exclude one-time items, losses per share were 3¢, just ahead of the 6¢ loss-per-share consensus on The Street, where analysts were looking for sales of $196.8 million, which the company also topped. &ld...
Source: Mass Device - August 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat wrightmedical Source Type: news

InVivo Therapeutics shares down as losses grow in Q2 earnings release
Shares in InVivo Therapeutics (NSDQ:NVIV) fell today after the medical device maker missed expectations on Wall Street with its second quarter results. The Cambridge, Mass-based company posted losses of $12.9 million, or $7.48 per share, up 104.1% as compared with the same period during the previous year. Losses per share were well behind the 41¢ expectations on Wall Street. “We continued to make progress in the second quarter of 2018, as the net proceeds of $13.5 million from our successful June 2018 public offering have put us in a position to focus on the initiation of the Inspire 2.0 Study. We are curre...
Source: Mass Device - August 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat InVivo Therapeutics Source Type: news

Second Sight shares down despite Q2 earnings beat
Shares in Second Sight Medical (NSDQ:EYES) fell today despite the opthalmalogical device maker beating loss per share expectations on Wall Street with its second quarter earnings results. The Los Angeles-based company posted losses of $8 million, or 12¢ per share, on sales of $1.9 million for the three months ended June 30, seeing losses grow 16.3% while shales shrunk 14.7% compared with the same period last year. Losses per share were just ahead of the 14¢ consensus on Wall Street. “I am pleased with the progress made during the past quarter with our Orion clinical and R&D programs. The technology...
Source: Mass Device - August 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Second Sight Source Type: news

Myomo shares down on Q2 miss
Shares in Myomo fell today after the wearable medical robotics maker missed expectations on Wall Street with its second quarter results. The Cambridge, Mass.-based company posted losses of $2.7 million, or 21¢ per share, on sales of $632,369 for the three months ended June 30, seeing losses grow 38.7% while sales grew 106.2% compared with the same period last year. Losses per share were just behind the 19¢ consensus on The Street. “We are pleased to report quarterly revenues growth of 106% year over year. We have opened new sales regions, added new O&P locations, and launched digital marketing...
Source: Mass Device - August 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Myomo Inc Source Type: news

Mylan eyes 'all alternatives' as quarterly profit falls short
Mylan NV said on Wednesday its board had set up a committee to review possible strategic alternatives, citing a tough U.S. environment for generic drugmakers. (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Valeritas tops sales, earnings estimates in Q2
Valeritas (NSDQ:VLRX) topped sales and earnings expectations on Wall Street this week with its second-quarter financial results. The Bridgewater, N.J.-based company posted a net loss of -$10.9 million on sales of $6.5 million for the three months ended June 30, for sales growth of 36% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Valeritas tops sales, earnings estimates in Q2 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 8, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Funding Roundup Pharmaceuticals Wall Street Beat Valeritas Source Type: news

Corindus shares fall on Q2 earnings release
Shares in Corindus Vascular Robotics (OTC:CVRS) fell today after the robotic surgical platform maker missed loss per share expectations on Wall Street but met sales consensus with its second quarter results. The Waltham, Mass.-based company posted losses of $9.9 million, or 6¢ per share, on sales of $1.7 million for the three months ended June 30, seeing losses grow compared with the same period last year. Losses per share were just behind the 5¢ per share consensus on The Street, where analysts were looking for sales of $1.7 million which the company met. “We have made meaningful progress advancing th...
Source: Mass Device - August 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Corindus Vascular Robotics Source Type: news

Ocular Therapeutix beats The Street with Q2 results
Shares in Ocular Therapeutix (NSDQ:OCUL) rose this week after the company topped expectations on Wall Street with its second-quarter financial results. The Bedford, Mass.-based company posted a net loss of -$13.8 million on sales of $648,000 for the three months ended June 30, representing sales growth of 48% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Ocular Therapeutix beats The Street with Q2 results appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 8, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Optical/Ophthalmic Pharmaceuticals Wall Street Beat oculartherapeutix Source Type: news

Endo shares soar on Street-beating Q2
Shares in Endo Pharmaceuticals (NSDQ:ENDP ) have risen nearly 20% so far today after the medical giant beat expectations on Wall Street with its second quarter results. The Dublin, Ireland-based company posted losses of $60.9 million, or 27¢ per share, on sales of $714.7 million for the three months ended June 30, seeing losses shrink 95.6% while sales shrunk 18.4% compared with the same period last year. Read the whole story on our sister site, Drug Delivery Business News The post Endo shares soar on Street-beating Q2 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Endo Pharmaceuticals Source Type: news

Mylan lowers outlook after Q2 earnings, sales miss estimates
Shares in Mylan (NSDQ:MYL) fell today after the pharmaceutical company missed expectations on Wall Street with its second-quarter financial results. The Canonsburg, Penn.-based company posted profits of $37.5 million, or 7¢ per share, on sales of $2.8 billion for the three months ended June 30, representing a bottom-line loss of -87.4% on a sales loss of 5% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Mylan lowers outlook after Q2 earnings, sales miss estimates appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - August 8, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Source Type: news

Drug maker Novo Nordisk expects lower U.S. prices next year
Novo Nordisk, the world's top maker of diabetes drugs, on Wednesday reported second-quarter operating profit broadly in line with forecasts, but said prices in the key U.S. market would be lower next year. (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

CHF Solutions shares down on Q2 earnings release
Shares in CHF Solutions (NSDQ:CHFS) fell today after the medical device maker missed sales expectations on Wall Street with its second quarter results. The Eden Prairie, Minn.-based company posted losses of $4.2 million, or 93¢ per share, on sales of $1.1 million for the three months ended June 30, for bottom-line growth of 70.1% on sales growth of 27.2% when compared with the same period last year. Losses per share were ahead of the $1.26 expectation on The Street, where analysts were looking for sales of $1.3 million, which the company missed. “We have continued to incrementally execute on our expans...
Source: Mass Device - August 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat CHF Solutions Inc. Source Type: news

TransEnterix shares fall despite Street-beating Q2
Shares in TransEnterix (NYSE:TRXC) fell today after the robotic surgical platform developer posted second quarter earnings that beat expectations on Wall Street, but showed growing losses. The Research Triangle Park, N.C.-based company posted losses of $34.3 million, or 17¢ per share, on sales of $6.4 million for the three months ended June 30, seeing losses grow 132.8% while sales grew 303.3% as compared with the same period last year. Adjusted to exclude one-time items, losses per share were 6¢, just in line with consensus on The Street, where analysts were looking for sales of $5.8 million. “Our per...
Source: Mass Device - August 7, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat TransEnterix Source Type: news